Upadacitinib 2023 Reimbursement Policy

The original drug Upadacitinib (Upadacitinib) has been marketed in China and has entered the scope of Class B medical insurance through relevant regulations of the National Medical Insurance Administration, but it is only reimbursed for patients who meet the indications. Its indications may include second-line treatment of refractory, moderate to severe atopic dermatitis in patients aged 12 years and above; second-line treatment of adult patients with active psoriatic arthritis, and second-line treatment of adult patients with moderate to severe active rheumatoid arthritis. Reimbursement ratios vary in different regions, and reimbursement prices may also vary. For specific relevant information, please consult the local medical insurance bureau or hospital.